Denali Therapeutics Inc. (DNLI) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $18.40: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 6.7:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 8.72; Below-average business quality; Negative price momentum.
Denali Therapeutics is a clinical-stage biopharmaceutical company using its proprietary TransportVehicle (TV) platform to deliver biologics across the blood-brain barrier for neurodegenerative and lysosomal storage diseases. Lead candidate tividenofusp alfa for Hunter syndrome... Read more
Sell if holding. Engine safety override at $18.40: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 6.7:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 8.72; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.0/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Denali Therapeutics Inc.
Latest news
- Morgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $40 — benzinga May 14, 2026 neutral
- BTIG Reiterates Buy on Denali Therapeutics, Maintains $39 Price Target — benzinga May 11, 2026 positive
- Wedbush Maintains Outperform on Denali Therapeutics, Lowers Price Target to $23 — benzinga May 8, 2026 positive
- Denali Therapeutics Q1 EPS $(0.69) Beats $(0.71) Estimate — benzinga May 7, 2026 positive
- Nancy Pelosi Stock Tracker Highlights Claude's Pharma Earnings Play: 'Will Be Interesting To See How This One Plays Out' — benzinga May 7, 2026 neutral
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinetividenofusp alfa10-K Item 1: 'Our most advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II'
Material Events(8-K, last 90d)
- 2026-04-03Item 1.02MEDIUMTakeda Pharmaceutical terminated the Collaboration Agreement for DNL593 (PTV:PGRN) on April 3, 2026. Decision driven by strategic considerations; not related to efficacy or safety. Rights revert to Denali 60 days after notice; no further financial obligations to Takeda.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $18.40: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 6.7:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 8.72; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $17.18. Score 5.0/10, moderate confidence.
Take-profit target: $30.82 (+70.2% upside). Prior stop was $17.18. Stop-loss: $17.18.
Concentration risk — Pipeline: tividenofusp alfa; Quality below floor (1.2 < 4.0).
Denali Therapeutics Inc. trades at a P/E of N/A (forward -7.3). TrendMatrix value score: 9.0/10. Verdict: Sell.
25 analysts cover DNLI with a consensus score of 4.4/5. Average price target: $35.
What does Denali Therapeutics Inc. do?Denali Therapeutics is a clinical-stage biopharmaceutical company using its proprietary TransportVehicle (TV) platform...
Denali Therapeutics is a clinical-stage biopharmaceutical company using its proprietary TransportVehicle (TV) platform to deliver biologics across the blood-brain barrier for neurodegenerative and lysosomal storage diseases. Lead candidate tividenofusp alfa for Hunter syndrome (MPS II) has a BLA under FDA priority review (PDUFA April 5, 2026). Net losses were $512.5M in 2025 with $966M in cash.